StockNews.AI
SLNO
StockNews.AI
8 hrs

SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm

1. Bragar Eagel & Squire is investigating Soleno for potential legal claims. 2. Scorpion Capital's report calls Vykat XR overpriced and potentially unsafe. 3. Soleno's stock dropped 7.41% after the report, closing at $71.63. 4. Investors with losses are encouraged to discuss their options with the law firm. 5. The investigation concerns possible violations of federal securities laws.

4m saved
Insight
Article

FAQ

Why Bearish?

The direct impact of the Scorpion report led to a significant stock price drop, indicating market concern about Vykat XR's safety and pricing. Historically, strong negative coverage by firms can significantly tarnish a company's market perception, often resulting in prolonged stock struggles.

How important is it?

The investigation and stock price drop highlight significant investor concerns, making it crucial for current and potential investors. Furthermore, issues around product safety can reshape market trust and long-term investor confidence.

Why Short Term?

Immediate reactions to the report suggest a potential short-term decline in stock valuations. However, longer-term impacts will depend on how Soleno addresses these allegations and recovers its market position.

Related Companies

SCORPHARINCY
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno (SLNO) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Soleno and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO) on behalf of Soleno stockholders. Our investigation concerns whether Soleno has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On August 15, 2025, Scorpion Capital ("Scorpion") published a report that described Soleno's only product, Vykat XR, as overpriced and potentially unsafe for children. Following publication of the Scorpion report, Soleno's stock price fell $5.73 per share, or 7.41%, to close at $71.63 per share on August 15, 2025. If you purchased or otherwise acquired Soleno shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News